Brief: Satsuma Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Business Highlights
28/03/2023 23:36
March 28 (Reuters) - Satsuma Pharmaceuticals Inc
STSA.O :
* SATSUMA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
* SATSUMA PHARMACEUTICALS INC - 36% WORKFORCE REDUCTION TO
BE
IMPLEMENTED EFFECTIVE MARCH 31, 2023
* SATSUMA PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $0.70
Source text for Eikon: ID:nGNX13BT6f
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon